Bristol Myers Squibb

Bristol Myers Squibb

Organization

Heard in 58 episodes across 22 shows since Sep 2025

Bristol Myers Squibb is a publicly traded American multinational pharmaceutical company headquartered in New Jersey. It discovers, develops, manufactures, and commercializes medicines, with major businesses in oncology, cardiovascular disease, and immunology; the podcast references primarily discuss its cancer treatments, partnerships, and stock performance.

Discussed inMarkets91%AI & Tech9%

Episodes

58
across 22 shows

This week

0
episodes on 0 shows

Expert statements

12
8 positive · 4 negative

Share of the conversation

Mentions of Bristol Myers Squibb per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.03‰0.05‰0.07‰0.1‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Aug 310.01‰1
Sep 10.02‰1
Sep 40.03‰1
Sep 130.01‰1
Sep 230.01‰1
Sep 300.01‰1
Oct 60.02‰1
Oct 80.02‰1
Oct 100.03‰1
Oct 120.07‰5
Oct 130.07‰1
Oct 150.07‰1
Oct 160.08‰1
Oct 190.03‰1
Oct 220.03‰2
Oct 260.03‰2
Oct 280.04‰1
Oct 290.03‰1
Oct 300.04‰1
Nov 20.03‰1
Nov 40.03‰1
Nov 60.02‰1
Nov 90.02‰1
Nov 200.02‰2

The full trend: rank, tone and why it is trending →

Email alert

Email me when Bristol Myers Squibb comes up on a podcast

One email a week at most, with the new episodes that mention Bristol Myers Squibb. Free, no account needed, unsubscribe in one click.

What experts have said about Bristol Myers Squibb

12 statements · 8 positive · 4 negative

  1. David SekeraPositiveOct 19, 2026· The Morning Filter

    Bristol Myers trades at a 15% discount to Morningstar’s valuation.

    “Bristol Myers stock is currently rated four stars, trades at a 15% discount”

    Listen at 32:42

    Open the episode · 4 Stocks to Buy for the Long-Term While They’re Still Undervalued
  2. David SekeraPositiveOct 19, 2026· The Morning Filter

    Bristol Myers earnings are expected to rebound from 2030 onward.

    “it will start to rebound in 2030 and thereafter”

    Listen at 35:23

    Open the episode · 4 Stocks to Buy for the Long-Term While They’re Still Undervalued
  3. Graig SuvannavejhPositiveOct 16, 2026· Biotech Hangout

    The FDA is likely to approve Bristol’s IPF drug.

    “it's hard to see that the FDA wouldn't approve this.”

    Listen at 30:07

    Open the episode · Episode 199 - October 16, 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

58 episodes featuring Bristol Myers Squibb, newest first